Germany To Disclose Rx Pricing Discounts, Setting A Potential Benchmark For Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The Germany health ministry’s decision to continue the 16% rebate and price moratorium for another year was disappointing for industry, yet predictable. More distressing is the decision to publicly release the final prices – which will likely have a domino effect on reimbursement in other EU member states.